Sol-Gel Technologies Ltd.
NASDAQ:SLGL
Overview | Financials
Company Name | Sol-Gel Technologies Ltd. |
Symbol | SLGL |
Currency | USD |
Price | 0.561 |
Market Cap | 15,619,756 |
Dividend Yield | 0% |
52-week-range | 0.334 - 1.575 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alon Seri-Levy |
Website | https://www.sol-gel.com |
An error occurred while fetching data.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD